Connect with us

Medical Devices

Scone Medical Solutions Inc Announces Issuance of U.S. Patent for Self-Contained Negative Pressure Environment

Avatar

Published

on

Issuance of U.S. Patent No. 10,967,204 for Novel Aerosol Containment Device

PHOENIX, April 28, 2021 /PRNewswire/ — Scone Medical Solutions Inc, a medical device company started in 2020, and focused on creating new methods of active barrier protection using negative pressure to reduce the risk of airborne transmission of infectious diseases in hospitals and triage settings, today announces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No 10,967,204, which is directed to a system of creating a Self-Contained Negative Pressure Environment (SCONE) to remove airborne particulates from an environment.

SCONE is a novel medical device that enables hospitals to maintain higher and safer airborne isolation precautions.

U.S. Patent 10,967,204 is directed toward the use of negative pressure in a small-capacity barrier protection device that actively removes airborne particulates emitted around a patient’s upper torso. The Self-Contained Negative Pressure Environment (SCONE) prevents exposure to pathogenic airborne particulates during triage and transportation, and treatments, including aerosol-generating procedures (AGPs) and end-of-life care. The SCONE system is a collapsible device with a flexible cover with arm access holes for medical professionals to reach in and treat patients by performing various procedures. The invention is further adaptable to patients and operating environments of various sizes.

This newly allowed patent is owned directly by Scone Medical Solutions Inc and represents a first-of-its-kind medical device that enables hospitals to maintain better airborne isolation precautions and safety standards, even during periods of high patient volume, and is designed to be used as an adjunct to airborne infection isolation rooms (AIIRs) and personal protective equipment (PPE). The SCONE device was Authorized for Emergency Use by the FDA on December 18, 2020 and is in the process of applying for full FDA approval.

“We are extremely pleased to receive a newly-issued Patent for our Self-Contained Negative Pressure Environment (SCONE) device. We commend our partners at NeoIP who assisted us in applying for a “fast track” accelerated examination COVID-19 application that resulted in this patent issuance in less than 7 months from our filing date. Their firm’s expertise and guidance has been an invaluable asset to our company, and we look forward to continued partnership with them in expanding our patent portfolio in the near future,” said Mike Adams, President and Chief Executive Officer of Scone Medical.

The highest risk of airborne infectious disease transmission is from actively infected patients to health care workers (HCWs) and other patients during Aerosol Generating Procedures (AGPs), particularly in the acute care/triage setting. The SCONE is a small capacity, disposable device that uses negative pressure to vacuum out aerosols emitted around a patient’s head and neck, adding an extra layer of active barrier protection to keep hospitals safe for healthcare workers and other patients. The SCONE can be quickly deployed for use and quickly disposed of after treatment.

If you would like more information about SCONE, please visit https://www.sconemed.com, email sales@sconemed.com or call (855) 949-4997.

About SCONE Medical Solutions Inc.

SCONE reduces the spread of transmissible diseases through the use of Self-Contained Negative Pressure Environments. The company uses technology developed in collaboration with Mayo Clinic to help hospitals protect their healthcare workers and other patients. Their low cost, disposable device is currently FDA EUA approved and is being manufactured here in the United States.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/scone-medical-solutions-inc-announces-issuance-of-us-patent-for-self-contained-negative-pressure-environment-301279215.html

SOURCE SCONE Medical Solutions Inc

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/scone-medical-solutions-inc-announces-issuance-of-u-s-patent-for-self-contained-negative-pressure-environment/?s=93

Medical Devices

Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates

Avatar

Published

on

 

WARRINGTON, Pa., May 13, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.), Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates.

Key Business and Financial Updates

  • Expanded the participating countries and sites in the Company’s Phase 2 global clinical study of istaroxime for the treatment of Early Cardiogenic Shock in severe acute heart failure patients. Cardiogenic shock is a severe form of heart failure marked by critically low blood pressure. This study builds upon observations from the acute heart failure program and will assess the ability of istaroxime to improve blood pressure in these patients and is expected to be completed in the second half of 2021.
     
  • Dosed the first patient in its Phase 2 clinical trial studying lucinactant, the Company’s KL4 surfactant, in acute lung injury in adults with COVID-19 associated acute respiratory distress syndrome (ARDS). The study is designed to evaluate key safety and physiological measures and is expected to be completed in Q3 2021.
     
  • Completed an equity financing raising approximately $30.0 million in gross proceeds during the first quarter of 2021, before deducting underwriting discounts and commissions and other estimated offering expenses. Net proceeds from the offering were approximately $27.4 million.
     
  • Announced pursuit of additional expedited patent protection for our lead asset istaroxime with the filing of a Track One prioritized patent application with the U.S. Patent and Trademark Office for a patent stemming from an application previously filed under the Patent Cooperation Treaty. Under the Track One program, the new istaroxime patent is expected to receive review and final disposition within a year of priority status being granted, rather than the customary three-year examination for non-prioritized examinations.
     
  • Extended the scientific collaboration with the University of Milan-Bicocca for further characterization and development of the Company’s oral SERCA2a compounds for the potential treatment of chronic and acute human heart failure.

“With additional countries and sites opening and dosing patients in our Phase 2 global clinical study of istaroxime for the treatment of Early Cardiogenic Shock in severe acute heart failure patients and the first patient dosed in our Phase 2 study of lucinactant in acute lung injury in adults with COVID-19 associated ARDS, our first quarter was off to a very productive start,” said Craig Fraser, President and Chief Executive Officer of Windtree. “As we look to the rest of the year, we see several potential value-creating milestones with data readouts anticipated in both Phase 2 trials. Additionally, we are actively engaged on the business development front, and are encouraged by the level of interest. Importantly, with the successful completion of a financing this quarter, our balance sheet provides the runway to continue to help fuel these current and planned development activities. We are focused on execution and a year of important milestones.”

Select Financial Results for the First Quarter ended March 31, 2021

For the first quarter ended March 31, 2021, the Company reported an operating loss of $9.1 million, compared to an operating loss of $6.7 million in the first quarter of 2020.

Research and development expenses were $4.4 million for the first quarter of 2021, compared to $3.5 million for the first quarter of 2020. The increase in research and development expenses is primarily due to costs related to the clinical development of istaroxime.

General and administrative expenses for the first quarter of 2021 were $4.7 million, compared to $3.2 million for the first quarter of 2020.

The Company reported a net loss of $9.0 million ($0.51 per basic share) on 17.7 million weighted-average common shares outstanding for the first quarter ended March 31, 2021, compared to a net loss of $6.5 million ($0.48 per basic share) on 13.7 million weighted average common shares outstanding for the comparable period in 2020.

As of March 31, 2021, the Company reported cash and cash equivalents of $38.5 million.

Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which will be filed with the Securities and Exchange Commission on May 13, 2021, which includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee’s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For more information, please visit the Company’s website at www.windtreetx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company’s clinical trials or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime, AEROSURF®, KL4 surfactant and the Company’s other product candidates; the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, aerosol delivery systems (ADS) and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the FDA or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; and the rate and degree of market acceptance of the Company’s product candidates, if approved. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Tables to Follow
+++++++++

Condensed Consolidated Balance Sheets

       

(in thousands, except share and per share data)

       
   

Three Months Ended

   

March 31,

   

2021

 

2020

   

Unaudited

   

ASSETS

       

Current Assets:

       

Cash and cash equivalents

 

$            38,490

 

$            16,930

Prepaid expenses and other current assets

 

851

 

1,188

Total current assets

 

39,341

 

18,118

         

Property and equipment, net

 

879

 

924

Restricted cash

 

154

 

154

Operating lease right-of-use assets

 

2,747

 

917

Intangible assets

 

77,090

 

77,090

Goodwill

 

15,682

 

15,682

Total assets

 

$          135,893

 

$          112,885

         

LIABILITIES & STOCKHOLDERS’ EQUITY

       

Current Liabilities:

       

Accounts payable

 

$                 939

 

$              1,161

Accrued expenses

 

3,744

 

3,813

Operating lease liabilities – current portion

 

392

 

805

Loans payable – current portion

 

2,409

 

352

Total current liabilities

 

7,484

 

6,131

         

Operating lease liabilities – non-current portion

 

2,438

 

201

Loans payable – non-current portion

 

 

2,423

Restructured debt liability – contingent milestone payments

 

15,000

 

15,000

Other liabilities

 

2,800

 

2,800

Deferred tax liabilities

 

16,683

 

16,778

Total liabilities

 

44,405

 

43,333

         

Stockholders’ Equity:

       

Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2021 and December 31, 2020

 

 

Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2021 and December 31, 2020; 26,257,089 and 16,921,506 shares issued at March 31, 2021 and December 31, 2020, respectively; 26,257,065 and 16,921,482 shares outstanding at March 31, 2021 and December 31, 2020, respectively

 

26

 

17

Additional paid-in capital

 

821,165

 

790,277

Accumulated deficit

 

(726,649)

 

(717,688)

Treasury stock (at cost); 24 shares

 

(3,054)

 

(3,054)

Total stockholders’ equity

 

91,488

 

69,552

Total liabilities & stockholders’ equity

 

$          135,893

 

$          112,885

 

Condensed Consolidated Statements of Operations

       

(in thousands, except per share data)

       
         
   

Three Months Ended

   

March 31,

   

2021

 

2020

         

Expenses:

       

Research and development

 

$         4,410

 

$         3,461

General and administrative

 

4,669

 

3,242

Total operating expenses

 

9,079

 

6,703

Operating loss

 

(9,079)

 

(6,703)

         

Other (expense) income:

       

Interest income

 

50

 

89

Interest expense

 

(41)

 

(44)

Other income, net

 

109

 

124

Total other (expense) income, net

 

118

 

169

         

Net loss

 

$        (8,961)

 

$        (6,534)

         

Net loss per common share

       

Basic and diluted

 

$          (0.51)

 

$          (0.48)

         

Weighted average number of common shares outstanding

       

Basic and diluted

 

17,695

 

13,697

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/windtree-therapeutics-reports-first-quarter-2021-financial-results-and-provides-key-business-updates-301290567.html

SOURCE Windtree Therapeutics, Inc.

 

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/windtree-therapeutics-reports-first-quarter-2021-financial-results-and-provides-key-business-updates/?s=93

Continue Reading

Medical Devices

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

Avatar

Published

on

DOORwaY-90 Study: Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in DOORwaY90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC).

DOORwaY90, which stands for “Duration of Objective Response with Arterial Y-90,” is the first prospective, U.S.-based multicenter, open-label single arm study of its kind. The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash. Study enrollment is underway, with the first patient enrolled at Inland Imaging Associates and Providence Sacred Heart Medical Center in Spokane, Washington.

“We are thrilled to enroll the first patient in DOORwaY90,” said Dr. Mark A. Turco, Global Chief Medical Officer and EVP of Research and Development for Sirtex. “This clinical trial studying a heterogeneous population of patients with HCC using personalized dosimetry planning has the potential to advance the treatment of HCC patients worldwide. We are deeply thankful to every clinical investigator and patient who will be part of this groundbreaking journey.”

With a planned enrollment of 100 subjects across 15 sites both academic and non-academic, DOORwaY90 is enrolling patients with Barcelona Clinic Liver Cancer (BCLC) Stage A, B1 and B2 who are not eligible for resection or ablation at the time of study entry. The study is unique because it is the first FDA-approved U.S.-based prospective trial to utilize and delineate personalized dosimetry treatment planning and to define actionable post-treatment dosimetric verification for endpoint assessment.

“It’s important for physicians to have confidence that their planned Y-90 dose is being delivered in the right amount and to the right place,” said Dr. Douglas Murrey, Vascular and Interventional Radiologist at Inland Imaging Associates and Providence Sacred Heart Medical Center in Spokane, Washington. “The personalized dosimetry component of the DOORwaY90 study will provide meaningful insights to advance our practice and patient outcomes.”

HCC is often diagnosed when potentially curative resection or transplantation is not feasible. SIRT has the potential to deliver a lethal dose of radiation to hepatic tumors, while sparing surrounding healthy liver tissue. In countries outside the U.S., SIRT has been successfully used to bridge patients to transplantation or downstage HCC to within transplantation criteria or resection.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/doorway-90-study/

Continue Reading

Medical Devices

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

Avatar

Published

on

Global Surgical Lasers Market Industry Report – https://www.reportlinker.com/p06033049/?utm_source=GNW

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gas Laser Systems segment is readjusted to a revised 10.6% CAGR for the next 7-year period.

– The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 12.8% CAGR
– The Surgical Lasers market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 12.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 8.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.
– Diode Laser Systems Segment to Record 9.7% CAGR
– In the global Diode Laser Systems segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$833.8 Million in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 11.1% CAGR through the analysis period.

Select Competitors (Total 42 Featured) –

  • Abbott Laboratories, Inc.
  • Alma lasers
  • Biolitec AG
  • Bison Medical Co. Ltd
  • Boston Scientific Corporation
  • Cynosure Inc.
  • Lumenis
  • Sharp light Technology
  • Spectranetics Corporation
  • Syneron Medical Ltd

Read the full report: https://www.reportlinker.com/p06033049/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Surgical Lasers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Surgical Lasers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Surgical Lasers by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Solid-State Laser
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Solid-State Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Solid-State Laser
Systems by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 7: World Current & Future Analysis for Gas Laser Systems
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Gas Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Gas Laser Systems by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Diode Laser
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Diode Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Diode Laser Systems by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Types by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Types by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Other Types by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Ambulatory Surgical Centers
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Ambulatory Surgical
Centers by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 19: World Current & Future Analysis for Hospitals by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Hospitals by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Hospitals by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Specialty Clinics
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Specialty Clinics by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Specialty Clinics by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Aesthetic by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Aesthetic by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Aesthetic by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Surgical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Surgical by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Surgical by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Other
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 34: USA Current & Future Analysis for Surgical Lasers by
Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 36: USA 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

CANADA
Table 43: Canada Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 45: Canada 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 46: Canada Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

JAPAN
Table 52: Japan Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 54: Japan 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 55: Japan Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

CHINA
Table 61: China Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 63: China 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 64: China Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 67: China Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

EUROPE
Table 70: Europe Current & Future Analysis for Surgical Lasers
by Geographic Region – France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 71: Europe Historic Review for Surgical Lasers by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Surgical Lasers by
Geographic Region – Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 75: Europe 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

FRANCE
Table 82: France Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 84: France 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 85: France Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 88: France Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

GERMANY
Table 91: Germany Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 93: Germany 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 94: Germany Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

ITALY
Table 100: Italy Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 102: Italy 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 103: Italy Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 109: UK Current & Future Analysis for Surgical Lasers by
Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: UK Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 111: UK 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 112: UK Current & Future Analysis for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

SPAIN
Table 118: Spain Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 120: Spain 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 121: Spain Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 122: Spain Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 123: Spain 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 124: Spain Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 125: Spain Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 126: Spain 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

RUSSIA
Table 127: Russia Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 128: Russia Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 129: Russia 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 130: Russia Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 131: Russia Historic Review for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 132: Russia 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 133: Russia Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 134: Russia Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 135: Russia 15-Year Perspective for Surgical Lasers by

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/global-surgical-lasers-market/

Continue Reading

Medical Devices

Carestream Health Advances X-ray Image Quality with Smart Noise Cancellation

Avatar

Published

on

Carestream Health has released Smart Noise Cancellation (SNC), a groundbreaking artificial intelligence (AI)-based technology that greatly improves image quality—producing images that are significantly clearer than with standard processing.

SNC has received FDA 510(k) Clearance and is available as an optional feature with Carestream’s ImageView Software powered by Eclipse—the intelligent image-processing engine behind the company’s innovative imaging software—on DRX-Evolution and DRX-Evolution Plus systems.

“Carestream is a leader in using AI for noise cancellation with X-ray images. Our team of imaging scientists has been able to separate image noise from sharpness and contrast using AI-based algorithms that result in remarkable image quality,” said Jill Hamman, Worldwide Marketing Manager, Global X-ray Solutions at Carestream. “This technology provides improved anatomical clarity, preservation of fine detail and better contrast-to-noise ratio for images acquired at a broad range of exposures, which can help improve diagnostic confidence and alleviate physician fatigue. It also enables radiology professionals to better optimize radiation dose.” Optimizing radiation dose is especially important with neonatal and pediatric diagnostic imaging, where imaging at the lowest possible dose is crucial for young patients.

Separating noise from an image has been a challenge for medical imaging scientists. Traditional noise reduction introduces blurring, which degrades image sharpness and might remove important anatomical information. Conversely, the more an image is sharpened, the more noise may be enhanced. Noise is often an undesirable by-product of image capture and can obscure critical anatomical data. Carestream’s SNC is able to isolate noise to produce images that are significantly clearer than with standard processing.

As the preferred level of noise on X-ray images is subjective—for example, some radiologists expect to see a certain degree of noise in images, which assures them that the patient was not overexposed—Carestream enables imaging professionals to adjust the amount of noise cancellation and exposure to meet their desired image quality.

Carestream Health notes objective testing demonstrated that SNC processing enables a 2x–4x noise reduction in flat image areas, preserves high frequency sharpness and improves contrast detail. Additionally, a blind Clinical Reader Study using board-certified radiologists found that 89.5 percent of all study ratings showed a slight to strong preference for SNC-processed images. Sixty-four percent of the diagnostic quality ratings improved—based on the RadLex rating scale—and 56 percent of these ratings improved from “limited” or “diagnostic” to “exemplary.”

Carestream Health notes when combined with SmartGrid software, Smart Noise Cancellation software promises benefits in gridless imaging where the removal of scatter typically leads to an increase in noise appearance.

“At Carestream, improving image quality is a top priority for our R&D team,” Ms. Hamman said. “Smart Noise Cancellation provides the ability to consistently deliver high-quality diagnostic images for healthcare providers and their patients.”

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/carestream-health-smart-noise-cancellation/

Continue Reading
Aviation5 days ago

JetBlue Hits Back At Eastern Airlines On Ecuador Flights

Blockchain5 days ago

“Privacy is a ‘Privilege’ that Users Ought to Cherish”: Elena Nadoliksi

AI2 days ago

Build a cognitive search and a health knowledge graph using AWS AI services

Blockchain2 days ago

Meme Coins Craze Attracting Money Behind Fall of Bitcoin

Energy3 days ago

ONE Gas to Participate in American Gas Association Financial Forum

SaaS4 days ago

Blockchain16 hours ago

Shiba Inu: Know How to Buy the New Dogecoin Rival

Fintech3 days ago

Credit Karma Launches Instant Karma Rewards

Blockchain4 days ago

Opimas estimates that over US$190 billion worth of Bitcoin is currently at risk due to subpar safekeeping

Blockchain4 days ago

Yieldly announces IDO

Esports3 days ago

Pokémon Go Special Weekend announced, features global partners like Verizon, 7-Eleven Mexico, and Yoshinoya

SaaS4 days ago

Blockchain2 days ago

Sentiment Flippening: Why This Bitcoin Expert Doesn’t Own Ethereum

Esports2 days ago

Valve launches Supporters Clubs, allows fans to directly support Dota Pro Circuit teams

SaaS4 days ago

Esports4 days ago

5 Best Mid Laners in League of Legends Patch 11.10

Cyber Security3 days ago

Top Tips On Why And How To Get A Cyber Security Degree ?

Business Insider2 days ago

Bella Aurora launches its first treatment for white patches on the skin

Esports1 day ago

‘Destroy Sandcastles’ in Fortnite Locations Explained

Blockchain4 days ago

Decentraland Price Prediction 2021-2025: MANA $25 by the End of 2025

Trending